Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2018 - 2025)

X4 Pharmaceuticals' Other Non-Current Liabilities history spans 8 years, with the latest figure at $10000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $10000.0; the TTM value through Dec 2025 reached $10000.0, changed 0.0%, while the annual FY2025 figure was $10000.0, 0.0% changed from the prior year.
  • Other Non-Current Liabilities reached $10000.0 in Q4 2025 per XFOR's latest filing, down from $525000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $29.4 million in Q1 2024 to a low of $10000.0 in Q4 2024.
  • Average Other Non-Current Liabilities over 5 years is $4.4 million, with a median of $525000.0 recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 98.13% in 2023, then surged 8310.86% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $496000.0 in 2021, then skyrocketed by 4565.52% to $23.1 million in 2022, then plummeted by 98.13% to $432000.0 in 2023, then crashed by 97.69% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Other Non-Current Liabilities are $10000.0 (Q4 2025), $525000.0 (Q3 2025), and $535000.0 (Q2 2025).